-

09:49:59 AM

IGXT Stock News

IGXT - IntelGenx Technologies Corp

05/31/23 8:00 AM

OTC : IGXT

IntelGenx Unveils Short-Term Commercial Objectives

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it is executing on a plan focussed on near-term revenue generation. “There is no question in my mind that IntelGenx has great science, services,

RHEA-AI

positive

05/17/23 8:00 AM

OTC : IGXT

IntelGenx Receives Amended DEL License to Conduct Third-Party Testing

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") a leading drug delivery company, is pleased

RHEA-AI

positive

05/11/23 4:05 PM

OTC : IGXT

earnings

IntelGenx Reports First Quarter 2023 Financial Results

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2023. All dollar amounts are expressed in U.S. currency, unless otherwise indicated,

RHEA-AI

neutral

05/04/23 4:30 PM

OTC : IGXT

conferencesearnings

IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 – Conference Call to Follow

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its first quarter 2023 financial results after market close on Thursday, May 11, 2023. An accompanying

RHEA-AI

neutral

04/27/23 4:30 PM

OTC : IGXT

IntelGenx Extends Period to Exercise Certain Warrants

IntelGenx Technologies Corp. (TSX: IGX) (OTCQX: IGXT) (the “ Company ” or “ IntelGenx ”) announces that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of warrants originally issued to Cantone

RHEA-AI

neutral

04/27/23 8:00 AM

OTC : IGXT

IntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Film

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that its co-developer, Chemo Research SL, through its agent and affiliate, Xiromed LLC (“Xiromed”), has received

RHEA-AI

neutral

04/17/23 8:15 AM

OTC : IGXT

fda approval

IntelGenx Announces FDA Approval of RIZAFILM® for the Treatment of Acute Migraine

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced

RHEA-AI

positive

04/13/23 9:17 AM

OTC : IGXT

IntelGenx Announces Organizational Changes to Support Global Growth Strategy

IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced various changes to its management team. Following the planned retirement of its founder and CEO, Horst G. Zerbe, PhD, the new executive

RHEA-AI

very positive

03/29/23 4:05 PM

OTC : IGXT

earnings

IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results

IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2022. All dollar amounts are expressed in U.S. currency, unless

RHEA-AI

neutral

03/24/23 4:15 PM

OTC : IGXT

earnings

IntelGenx Revises Fourth Quarter and Full Year 2022 Financial Results Reporting and Conference Call Date to March 29, 2023

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, further to its press release of March 23, 2023, it now plans to release its fourth quarter and full year 2022

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next